You are now leaving www.admabiologics.com
The link you have selected will take you outside of ADMA Biologics corporate website. The site you will be entering is intended for U.S. audiences only. Do you wish to continue?
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 05/12/21 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
76 |
| 05/12/21 | 8-K | Current report filing |
|
|
6 |
| 04/28/21 | 8-K | Current report filing |
|
|
3 |
| 04/12/21 | SC 13G/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
5 | |
| 04/08/21 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|
3 | |
| 04/07/21 | DEF 14A | Definitive proxy statements |
|
46 | |
| 03/26/21 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans |
|
5 | |
| 03/26/21 | PRE 14A | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
46 | |
| 03/25/21 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
119 |
| 03/25/21 | 8-K | Current report filing |
|
|
6 |
